Everything below concerns melanotan-2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
== Early life and education == Born 1972, Franz studied at Wellesley College and earned her bachelor's degree in 1995. She was a member of the Wellesley College cross country team. She moved to Massachusetts Institute of Technology for her graduate studies, where she worked under the supervision of Stephen J. Lippard and completed her PhD in 2001. Her research considered the nitric oxide reactivity of manganese, iron and cobalt tropocoronand ligands. She was an National Institutes of Health postdoctoral fellow from 2000 to 2003.
==== Eyelashes ==== The FP receptor agonist, bimatoprost, in the form of an 0.03% ophthalmic solution termed Latisse, is approved by the US Food and Drug Administration to treat hypotrichosis of the eyelashes, in particular to darken and lengthen eyelashes for cosmetic purposes. Also, bimatoprost may be used to treat small or underdeveloped eyelashes.
While earlier centuries also saw significant developments, the 20th century was distinguished by the unprecedented pace and global scale of economic, technological, and cultural changes. Still, advancing technology and medicine have had a great impact even in the Global South. Large-scale industry and more centralized media made brutal dictatorships possible on an unprecedented scale in the middle of the century, leading to wars that were also unprecedented. However, the increased communications contributed to democratization. Technological developments included the development of airplanes and space exploration, nuclear technology, advancement in genetics, and the dawning of the Information Age. Major political developments included the Israeli–Palestinian conflict, two world wars, and the Cold War. It also saw the former British Empire lose most of its remaining political power over Commonwealth countries, most notably by the dividing of the British crown into several sovereignties by the Statute of Westminster, the patriation of constitutions by the Canada Act 1982, and the Australia Act 1986, as well as the independence of countries like India, Pakistan, South Africa, and Ireland.
Sources: en.wikipedia.org
The Gospels of Matthew, Mark and Luke state that Joseph of Arimathea wrapped the body of Jesus in a "linen cloth" or "linen shroud" or just in "linen" (Greek: sindon) and placed it in a new tomb. The Gospel of John says that the body was wrapped in linen cloths (Greek: othonia), with a significant quantity of myrrh and aloes. The Gospel of John states that after the Resurrection of Jesus, "Simon Peter came, following him, and went into the tomb. He saw the linen wrappings lying there, and the cloth that had been on Jesus's head, not lying with the linen wrappings but rolled up in a place by itself." The Gospel of Luke states: "But Peter got up and ran to the tomb; stooping and looking in, he saw the linen cloths by themselves; then he went home, amazed at what had happened." In 1543, John Calvin, in his book Treatise on Relics, explained why the Shroud cannot be genuine:
== Use in research == Ibotenic acid used for the lesioning of rat's brains is kept frozen in a phosphate-buffered Saline Solution at a pH of 7.4, and can be kept for up to a year with no loss in toxicity. Injection of .05-.1 microliters of Ibotenic acid into the hippocampus at a rate of .1 microliter/min resulted in semi-selective lesioning. Hippocampal lesioning led to a considerable loss of cells in pyramidal cells (CA1-CA3) as well as granule cells in the dentate gyrus. Ibotenic acid lesioning also causes some damage to axons along the perforant pathway. Typically, when lesioning is done with other chemicals the subject cannot relearn a task. However, due to Ibotenic acid's reactivity with glutamate receptors such as the NMDA receptor, Ibotenic acid lesioning does allow the subject to relearn tasks. Ibotenic acid lesioning is thus preferred in studies where re-learning a task after lesioning is essential. Compared to other lesioning agents, Ibotenic acid is one of the most site-specific; however, less-damaging alternatives are presently sought.
== Sources == Picard, Jean-François; Pradoura, Elisabeth (19 March 1986). "Entretien avec Edgar Lederer". HISTCNRS. Archived from the original on July 24, 2023. "Edgar Lederer: Biochimiste; Médaille d'or du CNRS 1974" (in French). CNRS. Dosso, Diane (October–December 2000). "Les scientifiques français réfugiés en Amérique et la France Libre". Matériaux pour l'histoire de notre temps (in French). No. 60 "Les Etats-Unis et les réfugiés politiques européens : des années 1930 aux années 1950". pp. 34–40. doi:10.3406/mat.2000.403238. ISSN 0769-3206. Ettre, L. S. (June 1983). "Professor Edgar Lederer 75 Years Old". Editorial. Chromatographia. 17 (6): 299. doi:10.1007/BF02270660. eISSN 1612-1112. ISSN 0009-5893. Internet Archive sim_chromatographia_1983-06_17_6. Gehrke, Charles W.; Wixom, Robert L.; Bayer, Ernst, eds. (2001). Chromatography: a century of discovery 1900–2000: the bridge to the sciences/technology. Journal of Chromatography library, vol. 64. Elsevier. ISBN 978-0-444-50114-1. LCCN 2001053230. OL 8132723W. Google Books CiUyvgAACAAJ. Internet Archive chromatographyce0064unse. Institut für Zeitgeschichte (1983). "Lederer, Edgar". International Biographical Dictionary of Central European Emigrés 1933–1945. Vol. II / Part 1. München: K.G. Saur Verlag KG. p. 699. doi:10.1515/9783110970272.681. ISBN 978-3-598-10089-5. Laszlo, Pierre (2008). "Lederer, Edgar". Complete Dictionary of Scientific Biography. Vol. 22. Michigan: Charles Scribner's Sons. pp. 226–230. ISBN 978-0-684-80588-7. Academia.edu 6496303. Gale CX2830905849. Zlatkis, A. (November 1976). "The M. S.
Sources: en.wikipedia.org
These increases in coagulation factors may contribute to the development of stroke (see under § Side effects), but a precise association cannot be made at this stage. In a variety of clinical studies upon which FDA approval is based, Neumega showed effectivity in reducing thrombocytopenia in oncologic patients treated with myelosuppressant chemotherapeutic drugs as measured by significantly decreased need of platelet transfusions. Neumega is manufactured and sold by Wyeth. The drug is formulated in single-use vials containing 5 mg of oprelvekin (specific activity approximately 8 million units/mg) as a sterile, lyophilized powder. The FDA approved the drug in 1997.
===== Drug trafficking ===== 17 November 2013: Yong Vui Kong, a Malaysian found guilty of drug trafficking in 2007 and sentenced to death in 2008. He lost multiple appeals against his sentence to the Court of Appeal and President of Singapore. However, when changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 15 strokes of the cane. Yong was the first drug convict on death row to be spared the gallows since the 2013 law reforms. 6 January 2014: Subashkaran Pragasam, a Singaporean found guilty of trafficking heroin in 2008 and sentenced to death in 2012. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. 3 March 2014: Dinesh Pillai Reja Retnam, a Malaysian found guilty of trafficking heroin in 2009 and sentenced to death in 2011. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment on the grounds of diminished responsibility due to him suffering from depression when he committed the crime. 27 May 2014: Yip Mun Hei, a Singaporean convicted of trafficking heroin in 2008 and sentenced to death in 2009. When changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2014 to life imprisonment and 15 strokes of the cane. He had an accomplice Leong Soy Yip (also sentenced to death) whose fate remains unknown.
Fluorescence in situ hybridization (FISH) refers to using fluorescently labeled probe to hybridize to cytogenetic cell preparations. In addition to standard preparations FISH can also be performed on:
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.